---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-029347"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:19:18.892033+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCardia CardiAMP trial roll-in cohort shows +80 sec exercise tolerance, 82% fewer angina episodes at 6 months

## Summary
- Open-label roll-in cohort (N not given) met primary endpoint; no treatment-emergent major adverse cardiac events.
- Average exercise tolerance improved by 80 seconds at six-month follow-up vs. pre-treatment.
- Angina episodes reduced by an average of 82% at the six-month primary endpoint.
- 60% of patients showed substantial improvement in both exercise tolerance and angina reduction.
- Results compare favorably to FDA-approved therapies Ranolazine and EECP; data to be submitted for peer review.

## SEC filing metadata
- accession: 0001437749-25-029347
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925029347/0001437749-25-029347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925029347/bcda20250917_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-029347
- JSON: https://secwatch.observer/filing/0001437749-25-029347.json
- Plain text: https://secwatch.observer/filing/0001437749-25-029347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.